HighTide Therapeutics Announces Positive Phase III Results for HTD1801 in Type 2 Diabetes
HighTide Therapeutics, Inc. (HKG: 2511) today announced that its two Phase III clinical trials, SYMPHONY‑1 (NCT06350890)...
Takeda Reports 3.9% YoY Revenue Decline in H1 2025, Citing Neuroscience Slump and FX Headwinds
Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) released its first‑half 2025 financial results today,...
BrightGene Submits HKEX Prospectus, Aiming for Main‑Board Listing
BrightGene Bio‑Medical Technology Co., Ltd. (SHA: 688166) filed its prospectus with the Stock Exchange of...
Dizal Pharmaceutical Reports 73% Revenue Growth, Driven by Sunvozertinib and Golidocitinib
Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced its 2025 third‑quarter earnings today, reporting operating revenue...
JW Therapeutics & Regeneron Sign Expanded TCR‑T Collaboration, Unlocking $50 Million in Funding
JW Therapeutics Ltd. (HKG: 2126) announced today the signing of a supplementary strategic cooperation agreement...
Novo Nordisk Launches $9 Billion Unsolicited Bid for Metsera, Triggering Battle with Pfizer
Novo Nordisk A/S (NYSE: NVO) announced today an unsolicited offer of USD 9 billion for Metsera, Inc....
Thermo Fisher Secures $8.875B Clario Acquisition, Enhancing Digital‑Trial Endpoint Suite
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a definitive agreement to acquire Clario Holdings, Inc., a...
ModeX Therapeutics Locks $1 B+ Collaboration With Regeneron on Multispecific Antibody Technology
ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK) announced a milestone license and collaboration...
Everest Medicines Secures Exclusive Rights to VIS‑101 in Greater China, Potential 2026 Phase 3 Launch
Hong Kong‑listed Everest Medicines Limited (HKG: 1952) today announced a strategic agreement with Visara, Inc.,...
Bayer Secures FDA Approval for Elinzanetant, First Dual NK Therapy for VMS
Bayer (ETR: BAYN) announced that the U.S. Food and Drug Administration had granted marketing approval...
Ascletis Launches ASC36, a Once‑Monthly Injectable Targeting Obesity
China‑based Ascletis Pharma Inc. (HKG: 1672) announced the selection of ASC36, a once‑monthly subcutaneous injectable...
Pharmaron Expands CRO Footprint with 82.5% Acquisition of Biortus in $200 M Deal
China‑based Pharmaron Beijing Co., Ltd. (HKG: 3759) announced on October 28, 2025 that it will acquire an...
Sihuan Pharmaceutical Partners with Abalone Bio to Accelerate Obesity Therapeutics Development
China‑based Sihuan Pharmaceutical Holdings Group Ltd. (HKG: 0460) and U.S. biotech firm Abalone Bio signed...
MediCare Negotiation Begins: 535 Generic Drugs Reviewed for 2025 Drug Catalogue
The 2025 National Medical Insurance (MediCare) Negotiation kicked off at 8:30 AM, marking the start of...
Bayer Sells Avelox (Moxifloxacin) Business to HSG for Up to €260 Million
Bayer AG (ETR: BAYN) announced that it has entered into a Share Purchase Agreement (SPA)...
Lepu Biopharma Secures Conditional NMPA Approval for Becotatug Vedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma
Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody‑drug conjugate (ADC) Becotatug Vedotin (MGR003)...
Eli Lilly and NVIDIA Forge Record‑Breaking AI‑Powered Supercomputer for Pharma
Eli Lilly & Co. (NYSE: LLY) today announced a groundbreaking partnership with NVIDIA to build...
Shanghai Ark Biopharma Launches Phase II Trial of AK0610, a Next‑Generation RSV Prophylactic Antibody
Shanghai Ark Biopharmaceutical Co., Ltd. (ARK) today announced the official start of a Phase II clinical...
NovaBridge Biosciences Completes Rebranding, Launches New NBP Ticker on NASDAQ
NovaBridge Biosciences (formerly I‑Mab, NASDAQ: IMAB) announced today that its corporate name change is now...
Shanghai Junshi Biosciences Secures First Canadian Approval for LOQTORZI (Toripalimab) in Nasopharyngeal Cancer
Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced today that its programmed death‑1...